Skip to content

Study · Randomized controlled trial · n = 60 · 2026

6 results

Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.

Yang Z, Xu Y, Du H, Liu W, Chen H, Liu D, Zhang L, Wang C

Diabetes, obesity & metabolism3 Jun 2026Cited by 1 (Europe PMC)

PMID42236268 (opens in a new tab)PMCIDPMC13341338 (opens in a new tab)DOI10.1111/dom.70966 (opens in a new tab)PepBankPUB-42236268
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding low-dose tirzepatide to metformin reduced body weight more than metformin alone after 16 weeks.

    In plain wordsIn women with PCOS and overweight, adding tirzepatide to metformin led to more weight loss than metformin alone over 16 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at week 16
    Study

    n = 60

    Comparator
    Metformin 1000 mg BID monotherapy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg once weekly (with metformin 1000 mg BID) · 16 weeksAs given in this study (human).

    Measurements

    Weight change
    −1.7 kg
    metformin
    Weight change
    −10.4 kg
    tirzepatide plus metformin

    Source sentences

    Summary
    weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p < 0.001)
    2 context sentences
    Summary · context
    The primary outcome was the change in body weight.
    Summary · context
    Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding low-dose tirzepatide to metformin reduced body mass index more than metformin alone after 16 weeks.

    In plain wordsIn women with PCOS and overweight, adding tirzepatide to metformin lowered body mass index more than metformin alone over 16 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody mass index change at week 16
    Study

    n = 60

    Comparator
    Metformin 1000 mg BID monotherapy
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg once weekly (with metformin 1000 mg BID) · 16 weeksAs given in this study (human).

    Measurements

    BMI change
    −0.68 kg/m2
    metformin
    BMI change
    −4.12 kg/m2
    tirzepatide plus metformin

    Source sentences

    Summary
    body mass index (BMI) (-0.68 ± 1.82 vs. -4.12 ± 1.37 kg/m2; p < 0.001)
    2 context sentences
    Summary · context
    Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity.
    Summary · context
    Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding low-dose tirzepatide to metformin reduced visceral adipose tissue more than metformin alone after 16 weeks.

    In plain wordsIn women with PCOS and overweight, adding tirzepatide to metformin cut belly fat more than metformin alone over 16 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseVisceral adipose tissue change at week 16
    Study

    n = 60

    Comparator
    Metformin 1000 mg BID monotherapy
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg once weekly (with metformin 1000 mg BID) · 16 weeksAs given in this study (human).

    Measurements

    VAT change
    −4.67 cm2
    metformin
    VAT change
    −34.13 cm2
    tirzepatide plus metformin

    Source sentences

    Summary
    visceral adipose tissue (VAT) (-4.67 ± 9.59 vs. -34.13 ± 15.33 cm2; p < 0.001)
    2 context sentences
    Summary · context
    Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity.
    Summary · context
    Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding low-dose tirzepatide to metformin gave greater reductions in reproductive endocrine-metabolic parameters than metformin alone after 16 weeks.

    In plain wordsIn women with PCOS and overweight, adding tirzepatide to metformin improved hormone and metabolic measures more than metformin alone.

    Peptide
    Tirzepatide
    Outcome
    DecreaseReproductive endocrine-metabolic parameters at week 16
    Study

    n = 60

    Comparator
    Metformin 1000 mg BID monotherapy
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    5 mg once weekly (with metformin 1000 mg BID) · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    and reproductive endocrine-metabolic parameters.
    2 context sentences
    Summary · context
    Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity.
    Summary · context
    Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, menstrual cycle recovery was higher when tirzepatide was added to metformin than with metformin alone.

    In plain wordsIn women with PCOS and overweight, regular periods returned more often when tirzepatide was added to metformin than with metformin alone.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMenstrual cycle recovery
    Study

    n = 60

    Comparator
    Metformin 1000 mg BID monotherapy
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    5 mg once weekly (with metformin 1000 mg BID) · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Menstrual cycle recovery and total pregnancy rate were higher in the COM group than in the MET group (p = 0.013
    2 context sentences
    Summary · context
    Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity.
    Summary · context
    Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, the total pregnancy rate was higher when tirzepatide was added to metformin than with metformin alone.

    In plain wordsIn women with PCOS and overweight, pregnancy was more common when tirzepatide was added to metformin than with metformin alone.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTotal pregnancy rate
    Study

    n = 60

    Comparator
    Metformin 1000 mg BID monotherapy
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    5 mg once weekly (with metformin 1000 mg BID) · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Menstrual cycle recovery and total pregnancy rate were higher in the COM group than in the MET group (p = 0.013 and p = 0.014, respectively).
    2 context sentences
    Summary · context
    Barrier contraception was required for 8 weeks and pregnancy outcomes were subsequently evaluated between weeks 25 and 48.
    Summary · context
    Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.